搜索结果 | 泌尿系统常见疾病循证医学证据

证据分类

搜索结果

共搜索到11条与Black P. C.有关的结果

International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer

 2022 年发布于 European Urology 82 卷第 1 期

Roumiguie M. Kamat A. M. Bivalacqua T. J. Lerner S. P. Kassouf W. Bohle A. Brausi M. Buckley R. Persad R. Colombel M. Lamm D. Palou-Redorta J. Soloway M. Brothers K. Steinberg G. Lotan Y. Sylvester R. Witjes J. A. Black P. C.

文献简介 原文链接
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text

 2021 年发布于 Can Urol Assoc J 15 卷第 8 期

Bhindi B. Kool R. Kulkarni G. S. Siemens D. R. Aprikian A. G. Breau R. H. Brimo F. Fairey A. French C. Hanna N. Izawa J. I. Lacombe L. McPherson V. Rendon R. A. Shayegan B. So A. I. Zlotta A. R. Black P. C. Kassouf W.

Guidelines as Topic Humans Immunotherapy/*methods Societies Medical/*standards Urinary Bladder Neoplasms/*drug therapy antineoplastic protocols immunotherapy urinary bladder neoplasms urologic neoplasms Pfizer AstraZeneca Nektar Seattle Genetics DragonFly Therapeutics Non-CME services: Genentech AstraZeneca Merck Seattle Genetics Contracted research: Genentech Merck AstraZeneca Nektar Seattle Genetics Immunomedics. PCB─Consulting fees: AbbVie Asieris Pharmaceuticals Astellas AstraZeneca Bayer Biosyent Bristol-Myers Squibb EMD Serono Ferring Fergene H3 Biomedicine Janssen Merck Roche Sanofi TerSera Urogen Contracted research: iProgen. MTC─Consulting fees: Pfizer EMD Serono AstraZeneca Exelixis Eisai Seattle Genetics Astellas Contracted research: Exelixis Pfizer/EMD Serono Janssen Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus group 2020. MDG─Consulting fees: Inovio NuMab Janssen Merck GlaxoSmithKline Genentech Bristol-Myers Squibb Seattle Genetics Dracen Dragonfly Astellas Novartis Pfizer AstraZeneca Incyte Dendreon Eli Lilly EMD Serono Aileron Therapeutics Ownership interest: Rappta Therapeutics NPI: 1639140668. PG─Consulting fees: AstraZeneca Dyania Health EMD Serono Immunomedics Janssen Merck Mirati Therapeutics Genentech Pfizer Seattle Genetics Contracted Research: Bavarian Nordic Bristol-Myers Squibb Clovis Oncology Debiopharm Immunomedics Pfizer Merck QED Therapeutics GlaxoSmithKline Kure It Cancer Research Mirati Therapeutics. SG─Consulting fees: Merck Bristol-Myers Squibb Janssen Seattle Genetics AstraZeneca Contracted research: Bristol-Myers Squibb Pfizer Non-CME services: Exelixis. CJH─Consulting fees: Astellas Bristol-Myers Squibb Genentech Merck Eisai Seattle Genetics 2bPrecise Non-CME services: Astellas Bristol-Myers Squibb Genentech Eisai Seattle Genetics. AMK─Consulting fees: Abbott Molecular Arquer ArTara Asieris AstraZeneca BioClin Therapeutics Bristol-Myers Squibb Cepheid Cold Genesys Eisai Engene Inc. Ferring FerGene Imagin Janssen MDxHealth Medac Merck Pfizer Photocure ProTara Roviant Seattle Genetics Sessen Bio Theralase TMC Innovation US Biotest Contracted research: Adolor Bristol-Myers Squibb FKD Industries Heat Biologics Merck Photocure SWOG/NIH SPORE AIBCCR Clinical trials: FKD Merck Bristol-Myers Squibb Photocure SWOG Adolor Heat Biologics Laboratory research: NIH SPORE AIBCCR Educational grant: CEC Oncology Editorial board: European Urology Oncology Journal of Urology UroToday President of organization: International Bladder Cancer Network (IBCN) International Bladder Cancer Group (IBCG) IP Rights: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. LPL─Consulting fees: Pfizer Advisory Nursing board 2018 Lecture/Speaker/Expert Panel: ASCO Bladder Program 2019 Pfizer learning day 2019 ASCO Bladder Program Panel Member and Faculty 2019 Pfizer Learning Day Speaker 2019 BCAN Webinar Faculty 11/2020. JJM─Consulting fees: AstraZeneca Ferring Janssen Nucleix Foundation Medicine Contracted research: Epizyme Tesaro Abbvie Teaching an endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca Infinity Pharma Pfizer Flatiron Genentech Merck Seattle Genetics Contracted research: Astellas Bristol-Myers Squibb Genentech Merck. JER─Consulting fees: Merck Bristol-Myers Squibb AstraZeneca Astellas Seattle Genetics Boehringer Ingelheim Bayer Pfizer Roche/Genentech Mirati QED Therapeutics Janssen Pharmacyclics GlaxoSmithKline Contracted research/Clinical trial funding: Seattle Genetics Astellas Roche/Genentech Bayer AstraZeneca QED Therapeutics. NS─Consulting fees: Amgen Astellas AstraZeneca Bayer Bristol-Myers Squibb Dendreon Fergene Ferring Janssen Merck Myovant Nymox Pfizer Sanofi/Genzyme Sesen Bio Sun Pharma Tolmar. GDS─Consulting fees: Merck Janssen Ferring Bristol-Myers Squibb Pfizer Genentech Epivax Oncology AstraZeneca Fidia Cold Genesys EnGene Bio Aduro Biotech Dendreon FKD Therapies CiClomed Seattle Genetics Urogen PhotoCure. SITC staff: SMW—Shares owned: Pacific Biosciences Editas Medicine EG AK BL LL─Nothing to disclose.
文献简介 原文链接
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

 2021 年发布于 J Immunother Cancer 9 卷第 7 期

Galsky M. D. Balar A. V. Black P. C. Campbell M. T. Dykstra G. S. Grivas P. Gupta S. Hoimes C. J. Lopez L. P. Meeks J. J. Plimack E. R. Rosenberg J. E. Shore N. Steinberg G. D. Kamat A. M.

窄带成像非肌层浸润性膀胱癌经尿道膀胱肿瘤电切术安全性共识
文献简介 原文链接
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guerin

 2020 年发布于 Minerva Urol Nefrol 3 卷第 3 期

Li R. Sundi D. Zhang J. S. Kim Y. Sylvester R. J. Spiess P. E. Poch M. A. Sexton W. J. Black P. C. McKiernan J. M. Steinberg G. D. Kamt A. M. Gilbert S. M.

非肌层浸润性膀胱癌钬激光切除经尿道电切荟萃分析
文献简介 原文链接
Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis

 2020 年发布于 J Cancer Res Clin Oncol 9 卷第 10 期

Williams S. B. Cumberbatch M. G. K. Kamat A. M. Jubber I. Kerr P. S. McGrath J. S. Djaladat H. Collins J. W. Packiam V. T. Steinberg G. D. Lee E. Kassouf W. Black P. C. Cerantola Y. Catto J. W. F. Daneshmand S.

Humans Psychometrics *Quality of Life Surveys and Questionnaires Urinary Bladder Neoplasms/*therapy Calidad de vida Estudios de validación Neoplasias de la vejiga urinaria Neoplasms of the urinary bladder Quality of life Validation studies
文献简介 原文链接
Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer

 2019 年发布于 Front Oncol 201 卷第 6 期

Williams S. B. Hudgins H. K. Ray-Zack M. D. Chamie K. Smaldone M. C. Boorjian S. A. Daneshmand S. Black P. C. Kamat A. M. Goebell P. J. Seiler R. Schmitz-Drager B. Nawroth R. Baillargeon J. Klaassen Z. Kulkarni G. S. Kim S. P. Lee E. K. Holzbeierlein J. M. Hollenbeck B. K. Gore J. L.

Biomarkers Tumor/*urine Cystoscopy/methods *DNA Methylation Humans Urinary Bladder Neoplasms/*diagnosis/urine biomarkers methylation molecular diagnostics neoplasms urinary bladder urine analysis
文献简介 原文链接
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

 2018 年发布于 Scientific Reports 27 卷第期

Cumberbatch M. G. K. Jubber I. Black P. C. Esperto F. Figueroa J. D. Kamat A. M. Kiemeney L. Lotan Y. Pang K. Silverman D. T. Znaor A. Catto J. W. F.

文献简介 原文链接
Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review

 2018 年发布于现代泌尿生殖肿瘤杂志 32 卷第 5 期

Kamat A. M. Li R. O'Donnell M. A. Black P. C. Roupret M. Catto J. W. Comperat E. Ingersoll M. A. Witjes W. P. McConkey D. J. Witjes J. A.

文献简介 原文链接
Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer

 2018 年发布于 Oncotargets and Therapy 14 卷第 1 期

Tabayoyong W. B. Kamat A. M. O'Donnell M. A. McKiernan J. M. Ray-Zack M. D. Palou J. Brausi M. Black P. C. Williams S. B.

非肌层浸润性膀胱癌 TURBT 系统回顾化疗药物临床评价随机临床试验
文献简介 原文链接
Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy

 2017 年发布于 PLoS One 46 卷第期

Gakis G. Black P. C. Bochner B. H. Boorjian S. A. Stenzl A. Thalmann G. N. Kassouf W.

文献简介 原文链接
Predicting occult lymph node-positive disease at the time of radical cystectomy: a systematic review

 2016 年发布于 World J Surg Oncol 17 卷第期

Zargar H. Zargar-Shoshtari K. Dundee P. Black P. C.

文献简介 原文链接

 2022 年 发布于 European Urology 82 卷 第 1 期

Roumiguie M. Kamat A. M. Bivalacqua T. J. Lerner S. P. Kassouf W. Bohle A. Brausi M. Buckley R. Persad R. Colombel M. Lamm D. Palou-Redorta J. Soloway M. Brothers K. Steinberg G. Lotan Y. Sylvester R. Witjes J. A. Black P. C.

 2021 年 发布于 Can Urol Assoc J 15 卷 第 8 期

Bhindi B. Kool R. Kulkarni G. S. Siemens D. R. Aprikian A. G. Breau R. H. Brimo F. Fairey A. French C. Hanna N. Izawa J. I. Lacombe L. McPherson V. Rendon R. A. Shayegan B. So A. I. Zlotta A. R. Black P. C. Kassouf W.

 2021 年 发布于 J Immunother Cancer 9 卷 第 7 期

Galsky M. D. Balar A. V. Black P. C. Campbell M. T. Dykstra G. S. Grivas P. Gupta S. Hoimes C. J. Lopez L. P. Meeks J. J. Plimack E. R. Rosenberg J. E. Shore N. Steinberg G. D. Kamat A. M.

 2020 年 发布于 Minerva Urol Nefrol 3 卷 第 3 期

Li R. Sundi D. Zhang J. S. Kim Y. Sylvester R. J. Spiess P. E. Poch M. A. Sexton W. J. Black P. C. McKiernan J. M. Steinberg G. D. Kamt A. M. Gilbert S. M.

 2020 年 发布于 J Cancer Res Clin Oncol 9 卷 第 10 期

Williams S. B. Cumberbatch M. G. K. Kamat A. M. Jubber I. Kerr P. S. McGrath J. S. Djaladat H. Collins J. W. Packiam V. T. Steinberg G. D. Lee E. Kassouf W. Black P. C. Cerantola Y. Catto J. W. F. Daneshmand S.

 2019 年 发布于 Front Oncol 201 卷 第 6 期

Williams S. B. Hudgins H. K. Ray-Zack M. D. Chamie K. Smaldone M. C. Boorjian S. A. Daneshmand S. Black P. C. Kamat A. M. Goebell P. J. Seiler R. Schmitz-Drager B. Nawroth R. Baillargeon J. Klaassen Z. Kulkarni G. S. Kim S. P. Lee E. K. Holzbeierlein J. M. Hollenbeck B. K. Gore J. L.

 2018 年 发布于 Scientific Reports 27 卷 第期

Cumberbatch M. G. K. Jubber I. Black P. C. Esperto F. Figueroa J. D. Kamat A. M. Kiemeney L. Lotan Y. Pang K. Silverman D. T. Znaor A. Catto J. W. F.

 2018 年 发布于 现代泌尿生殖肿瘤杂志 32 卷 第 5 期

Kamat A. M. Li R. O'Donnell M. A. Black P. C. Roupret M. Catto J. W. Comperat E. Ingersoll M. A. Witjes W. P. McConkey D. J. Witjes J. A.

 2018 年 发布于 Oncotargets and Therapy 14 卷 第 1 期

Tabayoyong W. B. Kamat A. M. O'Donnell M. A. McKiernan J. M. Ray-Zack M. D. Palou J. Brausi M. Black P. C. Williams S. B.

 2017 年 发布于 PLoS One 46 卷 第期

Gakis G. Black P. C. Bochner B. H. Boorjian S. A. Stenzl A. Thalmann G. N. Kassouf W.

 2016 年 发布于 World J Surg Oncol 17 卷 第期

Zargar H. Zargar-Shoshtari K. Dundee P. Black P. C.

 2022 年发布于 European Urology 82 卷第 1 期

 2021 年发布于 Can Urol Assoc J 15 卷第 8 期

 2021 年发布于 J Immunother Cancer 9 卷第 7 期

 2020 年发布于 Minerva Urol Nefrol 3 卷第 3 期

 2020 年发布于 J Cancer Res Clin Oncol 9 卷第 10 期

 2019 年发布于 Front Oncol 201 卷第 6 期

 2018 年发布于 Scientific Reports 27 卷第期

 2018 年发布于现代泌尿生殖肿瘤杂志 32 卷第 5 期

 2018 年发布于 Oncotargets and Therapy 14 卷第 1 期

 2017 年发布于 PLoS One 46 卷第期

 2016 年发布于 World J Surg Oncol 17 卷第期